Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk ...

EKZ-102 is in IND-enabling development for the treatment of ALS and other neurodegenerative diseases, with a first-in-human clinical study planned for 2025 ...

The Subabul plant’s leaves and immature seeds are eaten in the form of soups or salads, both raw and cooked. It is a rich ...